Oncternal Therapeutics, Inc. (ONCT) Stock Price Soared By A Staggering 13.13%. Here’s What Happened.
Oncternal Therapeutics, Inc. (ONCT), a clinical-stage biopharmaceutical company specializing in manufacturing unique oncology therapies, announced the latest interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. At last check in […]
